The use of antiviral drugs in children

References

• Poole CL, Kimberlin DW. Antiviral drugs in newborn and children. Pediatr Clin North Am. 2017;64(6):1403–1415.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Brunton LL, Chabner B, et al. Goodman & Gilman's pharmacological basis of therapeutics. New York (NY): McGraw-Hill; 2015.
   Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;2014(4):CD008965.
   Google Scholar
• Malosh RE, Martin ET, Heikkinen T, et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data Meta-analysis of randomized controlled trials. Clin Infect Dis. 2018;66(10):1492–1500.
   PubMed Web of Science ®Google Scholar
• Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;2012(4):CD002744.
   Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 Update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1–e47.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018; 379(10):913–923.
   PubMed Web of Science ®Google Scholar
• Enioutina EY, Constance JE, Stockmann C, et al. Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opin Drug Metab Toxicol. 2015;11(12):1861–1878.
   PubMed Web of Science ®Google Scholar
• Beard KR, Brendish NJ, Clark TW. Treatment of influenza with neuraminidase inhibitors. Curr Opin Infect Dis. 2018;31(6):514–519.
   PubMed Web of Science ®Google Scholar
• Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512–524.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167–1175.
   PubMed Web of Science ®Google Scholar
• Standing JF, Nika A, Tsagris V, et al. Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza a virus infection in a neonatal intensive care unit. Antimicrob Agents Chemother. 2012;56(7):3833–3840. [PMC][https://doi.org/10.1128/AAC.00290-12] [22564835]
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Infectious Diseases. Recommendations for prevention and control of influenza in children, 2020–2021. Pediatrics. 2020;146(4):e2020024588.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Tetsuhashi M, Sato D. Oseltamivir phosphate – lifting the restriction on its use to treat teenagers with influenza in Japan. Pharmacoepidemiol Drug Saf. 2019;28(4):434–436.
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza a viruses. Proc Natl Acad Sci U S A. 2010;107(2):882–887.
   PubMed Web of Science ®Google Scholar
• Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009;361(17):1713–1714.
   PubMed Web of Science ®Google Scholar
• Heo YA. Baloxavir: first global approval. Drugs. 2018;78(6):693–697.
   PubMed Web of Science ®Google Scholar
• Chiopris G, Veronese P, Cusenza F, et al. Congenital cytomegalovirus infection: Update on diagnosis and treatment. Microorganisms. 2020;8(10):1516.
   Web of Science ®Google Scholar
• Kimberlin DW, Acosta EP, Sánchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197(6):836–845. ;.
   PubMed Web of Science ®Google Scholar
• Bilavsky E, Shahar-Nissan K, Pardo J, et al. Hearing outcome of infants with congenital cytomegalovirus and hearing impairment. Arch Dis Child. 2016;101(5):433–438.
   PubMed Web of Science ®Google Scholar
• Pinninti SG, Kimberlin DW. Management of neonatal herpes simplex virus infection and exposure. Arch Dis Child Fetal Neonatal. 2014; 99(3):F1–F5.
   Web of Science ®Google Scholar
• Kimberlin DW, Baley J, Committee on ID,. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics. 2013; 131(2):383–386.
   PubMedGoogle Scholar
• Sampson MR, Bloom BT, Lenfestey RW, et al. Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Pediatr Infect Dis J. 2014; 33(1):42–49.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for Use of Antiretroviral Agents in Pediatric HIV infection. Available from: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines.
   Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med. 1994;331(18):1173–1180.
   PubMed Web of Science ®Google Scholar
• Bhana N, Ormrod D, Perry CM, et al. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs. 2002;4(8):515–553.
   PubMedGoogle Scholar
• Dabis F, Bequet L, Ekouevi DK, et al. ANRS 1201/1202 DITRAME plus study group. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19(3):309–318.
   PubMed Web of Science ®Google Scholar
• Maswabi K, Ajibola G, Bennett K, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. Clin Infect Dis. 2021;72(3):388–393.
   PubMed Web of Science ®Google Scholar
• Clarke DF, Acosta EP, Cababasay M, IMPAACT P1110 Protocol Team, et al. Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1-Exposed neonates at risk of infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020;84(1):70–77. ;.
   PubMed Web of Science ®Google Scholar
• Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):477–487.
   PubMed Web of Science ®Google Scholar
• Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371–378.
   PubMed Web of Science ®Google Scholar
• El-Karaksy H, Mogahed EA, Abdullatif H, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67(5):626–630.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Romero R, Sokal EM, et al. (January 2017–October 2020). The safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to < 18 years old with chronic hepatitis C infection. Identifier NCT03022981. Available from: https://clinicaltrials.gov/ct2/show/NCT03022981.
   Google Scholar
• Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology. 2020;71(2):456–462.
   PubMed Web of Science ®Google Scholar
• Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66(4):1102–1110.
   PubMed Web of Science ®Google Scholar
• Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2020;71(1):31–43.
   PubMed Web of Science ®Google Scholar
• Garazzino S, Lo Vecchio A, Pierantoni L, et al. Epidemiology, clinical features and prognostic factors of pediatric SARS-CoV-2 infection: Results from an Italian Multicenter Study. Front Pediatr. 2021;9:649358.
   PubMed Web of Science ®Google Scholar
• Manti S, Licari A, Montagna L, et al. SARS-CoV-2 infection in pediatric population. Acta Biomed. 2020;91(11-S):e2020003.
   PubMedGoogle Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 – Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc. 2021;10(1):34–48.
   PubMed Web of Science ®Google Scholar
• Remdesivir by Gilead Sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment. Available from: https://www.fda.gov/safety/medical-product-safety-information/remdesivir-gilead-sciences-fda-warnsnewly-discovered-potential-drug-interaction-may-reduce.
   Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–1041.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 – Final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, GS-US-540-5773 Investigators, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020;383(19):1827–1837. PMC][https://doi.org/10.1056/NEJMoa2015301] [32459919].
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Wang CY, et al. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;76(8):1962–1968.
   PubMed Web of Science ®Google Scholar
• Venturini E, Montagnani C, Garazzino S, et al. Treatment of children with COVID-19: position paper of the italian society of pediatric infectious disease. Ital J Pediatr. 2020;46(1):139.
   PubMed Web of Science ®Google Scholar
• Montagnani C, Venturini E, L'Erario M, et al. Criteria for referral of pediatric SARS-CoV-2 infection: a real-life experience in the pandemic era. Ital J Pediatr. 2020;46(1):181.
   PubMed Web of Science ®Google Scholar
• Remdesivir nella terapia dei pazienti adulti con COVID-19 [Last version 2020 Nov 24, consulted 2020 Apr 01]. Available from: https://www.aifa.gov.it/documents/20142/1123276/remdesivir_update01_24.11.2020.pdf.
   Google Scholar
• Mulangu S, Dodd LE, Davey RT, Jr, et al. A randomized, controlled trial of Ebola virus disease Therapeutics. N Engl J Med. 2019;381(24):2293–2303.
   PubMed Web of Science ®Google Scholar
• Charan J, Kaur RJ, Bhardwaj P, et al. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol. 2021;14(1):95–103.
   PubMed Web of Science ®Google Scholar
• Wardell H, Campbell JI, VanderPluym C, et al. Severe acute respiratory syndrome coronavirus 2 infection in febrile neonates. J Pediatric Infect Dis Soc. 2020;9(5):630–635.
   PubMed Web of Science ®Google Scholar
• Frauenfelder C, Brierley J, Whittaker E, et al. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. Pediatrics. 2020;146(3):e20201701.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Martin R, Li J, Parvangada A, et al. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Antiviral Res. 2021;188:105033. [Inserted From Online [pubmed Mismatch]].
   PubMed Web of Science ®Google Scholar